Genetic study of non-Langerhans cell histiocytosis

The clinical features and prognosis of non-Langerhans cell histiocytosis (non-LCH) remained poorly defined. Although recurrent somatic activating mutations of BRAFV600E and additional genetic drivers of MAPK pathway had been discovered in ECD, difference of genetic alterations were discovered among different groups of non-LCH and the impact of these genetic mutations on clinical presentation in non-LCH remains elusive. To address these questions, we retrospectively studied the genomic analyses and outcomes of non-LCH patients in our center.